Sugi Predict

Sugi Predict / Compounds / Misonidazole

Misonidazole

Misonidazole

SCHEMBL18770100

COCC(O)Cn1ccnc1[N+](=O)[O-].O=[N+]([O-])n1ccnc1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.54
▸ LMNA P02545 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ HPGD P15428 1/20 0.37
▸ CA12 O43570 3/20 0.35
▸ CA1 P00915 3/20 0.35
▸ CA2 P00918 3/20 0.35
▸ CA9 Q16790 3/20 0.35
▸ MEN1 O00255 3/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ OPRK1 P41145 1/20 0.34
▸ TYMP P19971 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.33
▸ RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Misonidazole SCHEMBL51943 0.89 KMT2A (0.66) KMT2ALMNATHRBCYP2C19HPGD
Misonidazole SCHEMBL2168353 0.80 KMT2A (0.56) KMT2ALMNATHRBCYP2C19HPGD
Misonidazole SCHEMBL2833961 0.78 KMT2A (0.51) KMT2ALMNATHRBCYP2C19HPGD
SCHEMBL12396375 0.77 KMT2A (0.78) KMT2ALMNATHRBCYP2C19HPGD
Misonidazole SCHEMBL9762481 0.76 KMT2A (0.51) KMT2ALMNATHRBCYP2C19HPGD
Misonidazole SCHEMBL6680186 0.76 LMNA (0.58) KMT2ALMNATHRBCYP2C19CA12
SCHEMBL16473558 0.76 KMT2A (0.68) KMT2ALMNATHRBCYP2C19CA12
SCHEMBL9441423 0.76 KMT2A (0.62) KMT2ALMNATHRBCYP2C19HPGD
SCHEMBL6275185 0.76 KMT2A (0.55) KMT2ALMNATHRBCYP2C19HPGD
SCHEMBL16367290 0.75 KMT2A (0.60) KMT2ALMNATHRBCYP2C19HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116196427-A Compositions and methods for immune-mediated cancer therapy 泰克利森有限公司 2023-06-02 — — CN disclosed
US-20230133566-A1 COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY Teclison, Inc. 2023-05-04 — — US disclosed
CN-108472366-B Compositions and methods for immune-mediated cancer therapy 泰克利森有限公司 2023-03-17 — — CN disclosed
US-11534445-B2 Compositions and methods for immune-mediated cancer therapy TECLISON LIMITED (KY) 2022-12-27 — — US disclosed
US-20190070186-A1 COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY Teclison, Inc. 2019-03-07 — — US disclosed
EP-3365015-A1 COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY Teclison Limited (KY) 2018-08-29 — — EP disclosed
WO-2017070606-A1 COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY TECLISON LIMITED (KY) 2017-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133566-A1 COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY CD47, HIF1AN, HIF1A KMT2A 258/4885LMNA 3266/4885THRB 3783/4885
US-11534445-B2 Compositions and methods for immune-mediated cancer therapy CD47, HIF1AN, HIF1A KMT2A 258/4885LMNA 3266/4885THRB 3783/4885
US-20190070186-A1 COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY CD47, HIF1AN, HIF1A KMT2A 258/4885LMNA 3266/4885THRB 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.